Clinical Trials at Saint Francis Medical Center

As of June 2026, 85 paid clinical trials are recruiting at Saint Francis Medical Center, located at 211 ST FRANCIS DRIVE, CAPE GIRARDEAU, MO 63703, phone (573) 331-3080 in Cape Girardeau, Missouri. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

85 clinical trials at Saint Francis Medical Center

·Clear filters·↓ Download CSV

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

566 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

676 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

780 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting

Apply to this trial

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

for Hematopoietic and Lymphatic System Neoplasm

140 locations incl. Birmingham

Sponsor: National Cancer Institute LAO

Sex: All·Age: 2 Months+

Code: NCT02474160·Recruiting

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

Drug: Atezolizumab

338 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting

Apply to this trial